Novel immune therapy: antibody-recruiting strategy

Abstract Bifunctional molecules offer a novel therapeutic strategy by simultaneously binding to two distinct proteins. Antibody-recruiting molecules (ARMs), consisting of a target-binding terminus (TBT) that recognizes disease-associated proteins and an antibody-binding terminus (ABT) that engages endogenous natural antibodies, can specifically elicit immune responses against target pathogenic cells. Owing to the abundant presence of natural antibodies in the human body, antigen glycans are widely used as ABTs. This review highlights recent advancements in ARMs, with a focus on efficient ARM development using antigen glycans.